Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$307.80 USD

307.80
3,427,831

+6.66 (2.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $307.00 -0.80 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Stryker (SYK) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of 0.72% and 0.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can These 3 Medical Device Stocks Hit Earnings This Season?

by Zacks Equity Research

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.

Zacks Equity Research

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Stryker (SYK) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

by Zacks Equity Research

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Zacks Equity Research

Catalent (CTLT) Expands Its Facility Capabilities in Germany

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Zacks Equity Research

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

Zacks Equity Research

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

by Zacks Equity Research

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Zacks Equity Research

Patterson Companies (PDCO) Aims to Streamline Patient Experience

by Zacks Equity Research

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Zacks Equity Research

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

by Zacks Equity Research

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.